Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma.

Zhukova N, Rajagopal R, Lam A, Coleman L, Shipman P, Walwyn T, Williams M, Sullivan M, Campbell M, Bhatia K, Gottardo NG, Hansford JR.

Cancer Med. 2019 Jan;8(1):40-50. doi: 10.1002/cam4.1799. Epub 2018 Dec 19.

2.

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.

Packer RJ, Jakacki R, Horn M, Rood B, Vezina G, MacDonald T, Fisher MJ, Cohen B.

Pediatr Blood Cancer. 2009 Jul;52(7):791-5. doi: 10.1002/pbc.21935.

PMID:
19165892
3.

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE.

Neuro Oncol. 2014 Jan;16(2):310-7. doi: 10.1093/neuonc/not154. Epub 2013 Dec 4.

4.

Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.

Hwang EI, Jakacki RI, Fisher MJ, Kilburn LB, Horn M, Vezina G, Rood BR, Packer RJ.

Pediatr Blood Cancer. 2013 May;60(5):776-82. doi: 10.1002/pbc.24297. Epub 2012 Sep 13.

PMID:
22976922
6.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
7.

Bevacizumab in recurrent high-grade pediatric gliomas.

Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J.

Neuro Oncol. 2010 Sep;12(9):985-90. doi: 10.1093/neuonc/noq033. Epub 2010 Apr 2.

8.

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.

Parekh C, Jubran R, Erdreich-Epstein A, Panigrahy A, Bluml S, Finlay J, Dhall G.

J Neurooncol. 2011 Jul;103(3):673-80. doi: 10.1007/s11060-010-0444-x. Epub 2010 Nov 1. Erratum in: J Neurooncol. 2011 Jul;103(3):681.

PMID:
21038110
9.

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.

Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY.

Neuro Oncol. 2009 Oct;11(5):550-5. doi: 10.1215/15228517-2009-006. Epub 2009 Mar 30.

10.

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE.

J Clin Oncol. 2010 Jun 20;28(18):3069-75. doi: 10.1200/JCO.2009.26.8789. Epub 2010 May 17.

11.

Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.

Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J.

Jpn J Clin Oncol. 2013 Nov;43(11):1073-9. doi: 10.1093/jjco/hyt124. Epub 2013 Sep 3.

PMID:
24002900
12.

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.

Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY.

Neuro Oncol. 2010 Jun;12(6):603-7. doi: 10.1093/neuonc/nop073. Epub 2010 Feb 14.

13.

[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].

Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94. doi: 10.1016/j.neurol.2008.04.003. Epub 2008 Jun 3. French.

PMID:
18565358
14.

Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.

Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS.

Med Oncol. 2009;26(1):32-7. doi: 10.1007/s12032-008-9077-8. Epub 2008 May 22.

PMID:
18498064
15.

Fractionated stereotactic radiotherapy plus bevacizumab after response to bevacizumab plus irinotecan as a rescue treatment for high-grade gliomas.

Conde-Moreno AJ, García-Gómez R, Albert-Antequera M, Almendros-Blanco P, De Las Peñas-Bataller R, González-Vidal V, López-Torrecilla JL, Ferrer-Albiach C.

Rep Pract Oncol Radiother. 2015 May-Jun;20(3):231-8. doi: 10.1016/j.rpor.2015.01.004. Epub 2015 Feb 20.

17.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
18.

Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.

Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB.

J Pediatr Hematol Oncol. 2015 Aug;37(6):e341-6. doi: 10.1097/MPH.0000000000000371.

PMID:
26056795
19.

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

Lassaletta A, Scheinemann K, Zelcer SM, Hukin J, Wilson BA, Jabado N, Carret AS, Lafay-Cousin L, Larouche V, Hawkins CE, Pond GR, Poskitt K, Keene D, Johnston DL, Eisenstat DD, Krishnatry R, Mistry M, Arnoldo A, Ramaswamy V, Huang A, Bartels U, Tabori U, Bouffet E.

J Clin Oncol. 2016 Oct 10;34(29):3537-3543. doi: 10.1200/JCO.2016.68.1585.

PMID:
27573663
20.

Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: toxicity and efficacy trends.

Couec ML, André N, Thebaud E, Minckes O, Rialland X, Corradini N, Aerts I, Marec Bérard P, Bourdeaut F, Leblond P; Comité Pharmacologie of the SFCE.

Pediatr Blood Cancer. 2012 Jul 15;59(1):34-8. doi: 10.1002/pbc.24066. Epub 2012 Jan 27.

PMID:
22287258

Supplemental Content

Support Center